» Articles » PMID: 11124225

A Method for the Simultaneous Evaluation of the Activities of Seven Major Human Drug-metabolizing Cytochrome P450s Using an in Vitro Cocktail of Probe Substrates and Fast Gradient Liquid Chromatography Tandem Mass Spectrometry

Overview
Specialty Pharmacology
Date 2000 Dec 22
PMID 11124225
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s (CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2A6, and CYP2C8) was developed. This method uses an in vitro cocktail of specific substrates (midazolam, bufuralol, diclofenac, ethoxyresorufin, S-mephenytoin, coumarin, and paclitaxel) and fast gradient liquid chromatography tandem mass spectrometry. The assay incubation time is 20 min, which is in the linear range for all of the substrates, and the analysis time is 4 min/sample. Substrate specificity was confirmed by incubating Escherichia coli-expressed enzymes with the cocktail. Potent specific inhibitors of the seven enzymes (ketoconazole, quinidine, sulfaphenazole, tranylcypromine, quercetin, furafylline, and 8-methoxypsoralen) were evaluated in cocktail and individual substrate incubations. Five of these inhibitors were further studied to determine more precise IC(50) values for inhibition of the seven enzymes. The IC(50) values obtained in both cocktail and individual incubations were in good agreement with published values. This cocktail method offers an efficient, robust way to determine the cytochrome P450 inhibition profile of large numbers of compounds. The enhanced throughput of this method greatly facilitates its use to assess CYP inhibition as a drug candidate selection criterion.

Citing Articles

Inhibitor of the non-structural protein 2 protease shows promising efficacy in mouse models of chikungunya.

Metibemu D, Adeyinka O, Falode J, Hampton T, Crown O, Ojobor J Eur J Med Chem. 2024; 278:116808.

PMID: 39236495 PMC: 11440364. DOI: 10.1016/j.ejmech.2024.116808.


Preclinical Evaluation of Sigma 1 Receptor Antagonists as a Novel Treatment for Painful Diabetic Neuropathy.

Peng Y, Zhang A, Wei L, Welsh W ACS Pharmacol Transl Sci. 2024; 7(8):2358-2368.

PMID: 39144554 PMC: 11320727. DOI: 10.1021/acsptsci.4c00186.


Safety Aspects of Herb Interactions: Current Understanding and Future Prospects.

Hazra S, Singh P Curr Drug Metab. 2024; 25(1):28-53.

PMID: 38482621 DOI: 10.2174/0113892002289753240305062601.


Prospective Prediction of Dapaconazole Clinical Drug-Drug Interactions Using an In Vitro to In Vivo Extrapolation Equation and PBPK Modeling.

Antunes N, Moreira F, Kipper K, Couchman L, Lebre D, Johnston A Pharmaceuticals (Basel). 2023; 16(1).

PMID: 36678526 PMC: 9861162. DOI: 10.3390/ph16010028.


Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis.

Oxombre B, Madouri F, Journe A, Ravez S, Woitrain E, Odou P Int J Mol Sci. 2022; 23(19).

PMID: 36233193 PMC: 9569529. DOI: 10.3390/ijms231911893.